Emily A. Stevens

9.3k total citations
15 papers, 546 citations indexed

About

Emily A. Stevens is a scholar working on Genetics, Hematology and Health, Toxicology and Mutagenesis. According to data from OpenAlex, Emily A. Stevens has authored 15 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 5 papers in Hematology and 4 papers in Health, Toxicology and Mutagenesis. Recurrent topics in Emily A. Stevens's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Toxic Organic Pollutants Impact (3 papers). Emily A. Stevens is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Toxic Organic Pollutants Impact (3 papers). Emily A. Stevens collaborates with scholars based in United States and South Africa. Emily A. Stevens's co-authors include Christopher A. Bradfield, Joshua D. Mezrich, Rachel B. Salit, H. Joachim Deeg, Bart L. Scott, Kelsey K. Baker, Ted Gooley, Cristina P. Rodriguez, Elizabeth E. Dunham and Edward Glover and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Clinical Cancer Research.

In The Last Decade

Emily A. Stevens

15 papers receiving 537 citations

Peers

Countries citing papers authored by Emily A. Stevens

Since Specialization

Citations

This map shows the geographic impact of Emily A. Stevens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily A. Stevens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily A. Stevens more than expected).

Fields of papers citing papers by Emily A. Stevens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily A. Stevens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily A. Stevens. The network helps show where Emily A. Stevens may publish in the future.

Co-authorship network of co-authors of Emily A. Stevens

This figure shows the co-authorship network connecting the top 25 collaborators of Emily A. Stevens. A scholar is included among the top collaborators of Emily A. Stevens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily A. Stevens. Emily A. Stevens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	aBnormal motION capture In aCute Stroke (BIONICS): A Low-Cost Tele-Evaluation Tool for Automated Assessment of Upper Extremity Function in Stroke Patients 2023 ·Neurorehabilitation and neural repair ·(unknown), (unknown), Emily A. Stevens, (unknown), (unknown), (unknown), Xiaoqian Jiang, Sean I. Savitz, Shayan Shams	4
2	Targeted Sequencing Improves DIPSS-Plus Prognostic Scoring in Myelofibrosis Patients Undergoing Allogeneic Transplantation 2020 ·Biology of Blood and Marrow Transplantation ·Emily A. Stevens, Isaac Jenkins, Lan Beppu, Qing Zhang, Rachel B. Salit, Keith R. Loeb, H. Joachim Deeg, Jerald P. Radich	9
3	Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis 2019 ·Bone Marrow Transplantation ·Rachel B. Salit, Bart L. Scott, Emily A. Stevens, Kelsey K. Baker, Ted Gooley, H. Joachim Deeg	34
4	JAK Inhibitors Prior to Allogeneic Stem Cell Transplant for Patients with Myelofibrosis: A Prospective Study 2018 ·Biology of Blood and Marrow Transplantation ·Rachel B. Salit, Emily A. Stevens, Kelsey K. Baker, Bart L. Scott, Ted Gooley, H. Joachim Deeg	1
5	Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes 2017 ·Biology of Blood and Marrow Transplantation ·Bethany Samuelson Bannow, Rachel B. Salit, Barry E. Storer, Emily A. Stevens, David Wu, Cecilia C.S. Yeung, Min Fang, Effie W. Petersdorf, Michael Linenberger, Janghee Woo, Mohamed L. Sorror, Kris Doney, Brenda M. Sandmaier, H. Joachim Deeg, Bart L. Scott	35
6	An unusual case of co-existing classic mantle cell lymphoma and transformed lymphoma with Burkitt-like features with leukemic presentation 2016 ·Journal of Hematopathology ·Geling Li, Yi Zhou, Sindhu Cherian, Emily A. Stevens, Ryan D. Cassaday, Xueyan Chen	1
7	The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I 2015 ·Clinical Cancer Research ·Julia E. Maxson, Samuel B. Luty, Jason D. MacManiman, Jason C. Paik, Jason Gotlib, Peter L. Greenberg, (unknown), Samantha L. Savage, Melissa L. Abel, Christopher A. Eide, Marc Loriaux, Emily A. Stevens, Jeffrey Tyner	37
8	Genomic medicine and targeted therapy for solid tumors 2014 ·Journal of Surgical Oncology ·Emily A. Stevens, Cristina P. Rodriguez	9
9	The aryl hydrocarbon receptor: a perspective on potential roles in the immune system 2009 ·Immunology ·Emily A. Stevens, Joshua D. Mezrich, Christopher A. Bradfield	332
10	The Aryl Hydrocarbon Receptor Signaling Pathway Is Modified through Interactions with a Kelch Protein 2006 ·Molecular Pharmacology ·Elizabeth E. Dunham, Emily A. Stevens, Edward Glover, Christopher A. Bradfield	14
11	The Teratogenic Sensitivity to 2,3,7,8-Tetrachlorodibenzo-p-dioxin Is Modified by a Locus on Mouse Chromosome 3 2005 ·Molecular Pharmacology ·(unknown), Emily A. Stevens, Adam L. Liss, Norman R. Drinkwater, Christopher A. Bradfield	11
12	Transforming Growth Factor-β3 Restores Fusion in Palatal Shelves Exposed to 2,3,7,8-Tetrachlorodibenzo-p-dioxin 2005 ·Journal of Biological Chemistry ·(unknown), Emily A. Stevens, Christopher A. Bradfield	40
13	Phase II Study of Arsenic Trioxide Plus Ascorbic Acid for Relapsed and Refractory Lymphoid Malignancies: A Wisconsin Oncology Network Study. 2004 ·Blood ·Brad S. Kahl, Harish G. Ahuja, Federico Augusto Sanchez, (unknown), Peter M. Voorhees, Emily A. Stevens, (unknown), (unknown), KyungMann Kim, Howard H. Bailey	2
14	Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. 2004 ·Blood ·Brad S. Kahl, (unknown), Jules H. Blank, Anthony J. Jaslowski, (unknown), Wayne A. Bottner, (unknown), Thomas McFarland, (unknown), (unknown), Emily A. Stevens, Jens C. Eickhoff, Walter Longo	9
15	Some effects of tempo changes on stereotyped rocking movements of low-lewel mentally retarded subjects. 1971 ·PubMed ·Emily A. Stevens	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact